American Society of Hirudotherapy

Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process

Research article published in Journal of vascular research (1994)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Drug DevelopmentWalters TK et al. · Journal of vascular research, 1994

Abstract

Vascular injury, activation of the coagulation system and thrombosis are common initial events in the accelerated atherosclerotic process. The role of thrombin generated at the site of aortic injury in the subsequent neointimal proliferation was studied in rabbits (n = 16) 3 weeks after balloon catheter injury. In half of these animals, potent thrombin antagonists, r-hirudin and P-PACK, were administered to prevent acute thrombotic events. Compared to aortas with intact endothelium (n = 8), aortas de-endothelialised 21 days earlier showed neointimal hyperplasia as measured by the intimal/medial ratio (0.68 vs. 0.04, injured vs. normal aortas) and an increase in both total cholesterol (4.08 vs. 3.31 mg/g, p < 0.05) and lipid peroxide content (31.3 vs. 1.1 nmol/g; p < 0.001). Neointimal hyperplasia following endothelial denudation was inhibited in rabbits treated with thrombin-antagonists (0.27 vs. 0.68, treated vs. untreated, p = 0.012) and neither total cholesterol (3.48 mg/g) nor lipid peroxide content (1.5 nmol/g) differed significantly from that of intact arteries. By demonstrating a strong relationship between thrombin generation following de-endothelialisation and the progressive intimal proliferation, this study supports the hypothesis that thrombin is an important contributor to restenosis after vascular injury. The highly atherogenic lipid peroxidation seems to be linked to the early, thrombin-mediated events, as it was completely prevented by adequate thrombin antagonism.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsAntithrombinsAorta, ThoracicArteriosclerosisCatheterizationCholesterolEndothelium, VascularHyperplasiaLipid PeroxidationLipid PeroxidesMaleMicroscopy, Electron, ScanningRabbitsThrombinThrombin TimeThrombosis

Summary

In rabbit aortas, balloon denudation caused neointimal hyperplasia and rises in cholesterol and lipid peroxides; the thrombin antagonists r-hirudin and P-PACK reduced hyperplasia (intimal/medial ratio 0.27 vs 0.68) and prevented the lipid peroxide rise.

Why This Matters for Hirudotherapy

This study examined the role of thrombin generation in neointimal proliferation and atherogenesis following balloon-catheter aortic injury in rabbits, administering thrombin antagonists (r-hirudin and P-PACK) to half the animals to prevent acute thrombotic events. Thrombin-antagonist treatment significantly inhibited neointimal hyperplasia (intimal/medial ratio 0.27 vs. 0.68, p = 0.012), and neither total cholesterol (3.48 mg/g) nor lipid peroxide content (1.5 nmol/g) in treated arteries differed significantly from intact arteries. The abstract refers to 'r-hirudin' without identifying it as leech-derived; its connection to hirudotherapy is inferable from general knowledge only. The study is an experimental animal model of an isolated recombinant molecule, not a clinical trial or live hirudotherapy evaluation.

Citation

Reference (Vancouver style)

Walters TK, Gorog DA, Wood RF. Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process. J Vasc Res. 1994;31(3):173-177. doi:10.1159/000319584. PMID: 8148468

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.